* severe allergy to any arb or ace-inhibitor, including angioedema * in the intensive care unit at screening. * home meds include any kind of ace inhibitor or arb * acute kidney injury (50% reduction in gfr from baseline at admission to any time during treatment in the study treatment arm) * hyperkalemia \>5.0 mmol/l at baseline or any time during treatment in the study treatment arm * creatinine clearance \< 30 ml/min at baseline or any time during treatment in the study treatment arm

* severe allergy to any arb or ace-inhibitor, including angioedema * in the intensive care unit at screening. * home meds include any kind of ace inhibitor or arb * acute kidney injury (50% reduction in gfr from baseline at admission to any time during treatment in the study treatment arm) * hyperkalemia \>5.0 mmol/l at baseline or any time during treatment in the study treatment arm * creatinine clearance \< 30 ml/min at baseline or any time during treatment in the study treatment arm

- severe allergy to any arb or ace-inhibitor, including angioedema - in the intensive care unit at screening. - home meds include any kind of ace inhibitor or arb - acute kidney injury (50% reduction in gfr from baseline at admission to any time during treatment in the study treatment arm) - hyperkalemia >5.0 mmol/l at baseline or any time during treatment in the study treatment arm - creatinine clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm

- severe allergy to any arb or ace-inhibitor, including angioedema - in the intensive care unit at screening. - home meds include any kind of ace inhibitor or arb - acute kidney injury (50% reduction in gfr from baseline at admission to any time during treatment in the study treatment arm) - hyperkalemia >5.0 mmol/l at baseline or any time during treatment in the study treatment arm - creatinine clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm